Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats

被引:111
作者
Tamura, S
Ohike, A
Ibuki, R
Amidon, GL
Yamashita, S
机构
[1] Fujisawa Pharmaceut Co Ltd, Yodogawa Ku, Osaka 5328514, Japan
[2] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
[3] Setsunan Univ, Fac Pharmaceut Sci, Osaka 57301, Japan
关键词
intestinal permeability; drug absorption; tacrolimus; P-glycoprotein efflux; multidrug resistance;
D O I
10.1002/jps.10041
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The objective of this study is to investigate the role of P-glycoprotein (P-gp), a membrane efflux pump associated with multidrug resistance (MDR) and a known substrate for tacrolimus, in determining the regional intestinal permeability of tacrolimus in rats. Thus, isolated segments of rat jejunum, ileum, or colon were perfused with tacrolimus solutions containing polyethoxylated hydrogenated castor oil 60 surfactant, and with or without verapamil, a P-gp substrate used to reverse the MDR phenotype. The results indicated that the intrinsic permeability of tacrolimus in the jejunum, calculated on the basis of the concentration of non-micellized free tacrolimus, was quite high (similar to 1.4 x 10(-4) cm/s). The apparent permeability (P-app) in the jejunum was unaffected by the presence of verapamil; however, the P-app in the ileum and the colon increased significantly in the presence of verapamil and were similar to the values observed in the jejunum. The results suggest that systemic absorption of tacrolimus from the gastrointestinal tract could be significantly affected by P-gp efflux mechanisms. It is also possible that differences in P-gp function at various intestinal sites in a subject or at a given intestinal site in various subjects could lead to large intra- and interindividual variability in bioavailability of tacrolimus following oral administration. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:719 / 729
页数:11
相关论文
共 41 条
[1]   THEORETICAL AND EXPERIMENTAL STUDIES OF TRANSPORT OF MICELLE-SOLUBILIZED SOLUTES [J].
AMIDON, GE ;
HIGUCHI, WI ;
HO, NFH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1982, 71 (01) :77-84
[2]   ESTIMATING HUMAN ORAL FRACTION DOSE ABSORBED - A CORRELATION USING RAT INTESTINAL-MEMBRANE PERMEABILITY FOR PASSIVE AND CARRIER-MEDIATED COMPOUNDS [J].
AMIDON, GL ;
SINKO, PJ ;
FLEISHER, D .
PHARMACEUTICAL RESEARCH, 1988, 5 (10) :651-654
[3]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[4]   New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine [J].
Armstrong, VW ;
Oellerich, M .
CLINICAL BIOCHEMISTRY, 2001, 34 (01) :9-16
[5]   SELECTIVE PARACELLULAR PERMEABILITY IN 2 MODELS OF INTESTINAL-ABSORPTION - CULTURED MONOLAYERS OF HUMAN INTESTINAL EPITHELIAL-CELLS AND RAT INTESTINAL SEGMENTS [J].
ARTURSSON, P ;
UNGELL, AL ;
LOFROTH, JE .
PHARMACEUTICAL RESEARCH, 1993, 10 (08) :1123-1129
[6]   Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery [J].
Benet, LZ ;
Izumi, T ;
Zhang, YC ;
Silverman, JA ;
Wacher, VJ .
JOURNAL OF CONTROLLED RELEASE, 1999, 62 (1-2) :25-31
[7]   EVIDENCE FOR A POLARIZED EFFLUX SYSTEM FOR PEPTIDES IN THE APICAL MEMBRANE OF CACO-2 CELLS [J].
BURTON, PS ;
CONRADI, RA ;
HILGERS, AR ;
HO, NFH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 190 (03) :760-766
[8]  
Collett A, 1999, J PHARMACOL EXP THER, V288, P171
[9]   Comparison between permeability coefficients in rat and human jejunum [J].
Fagerholm, U ;
Johansson, M ;
Lennernas, H .
PHARMACEUTICAL RESEARCH, 1996, 13 (09) :1336-1342
[10]   Tacrolimus oral bioavailability doubles with coadministration of ketoconazole [J].
Floren, LC ;
Bekersky, I ;
Benet, LZ ;
Mekki, Q ;
Dressler, D ;
Lee, JW ;
Roberts, JP ;
Hebert, MF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (01) :41-49